Figure 4From: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot StudySFNSL subscore analysis. (A) A decrease in frequency of symptoms occurred in both groups over the dosing period, which did not differ significantly. (B) Severity of symptoms remained unchanged in the placebo group, whereas a decrease was noted in the ARA 290 (p < 0.05).Back to article page